Reports about an impending deal have been circulating for some time and now the companies confirm that an agreement has been reached.
Springworks, headquartered in Stamford, Connecticut, primarily focuses on precision oncology and the treatment of rare genetic diseases. The company has developed, among other things, a systemic standard-of-care the...
Merck KGaA acquires American company in €3.0 billion deal
Germany’s Merck is completing the acquisition of Springwork Therapeutics for 3 billion euros.
Vill du få åtkomst till allt?
Prova 30 dagar för 0 kr.
Inga bindningstider eller kortuppgifter krävs.
Prova nu
Köp en prenumeration
Utforska våra prenumerationslösningar och välj den som passar dina behov.
Välj din prenumeration